British Columbia Prescriber Feedback Program - Antimicrobial Resistance

Audit and feedback is a well-established strategy for improving the quality of care in primary healthcare settings. It involves the systematic collection and analysis of healthcare data, followed by the provision of information to healthcare providers to improve the quality of care.

Antimicrobial resistance is a growing global health problem, fueled in part by unnecessary antibiotic use. Most antibiotics are prescribed in the community, especially for respiratory infections, and many of these prescriptions provide little or no benefit, particularly for viral illnesses. Effective antimicrobial stewardship in primary care is essential.

Based in British Columbia, Canada, the Therapeutics Initiative's Portrait program provides family physicians and nurse practitioners with individualized prescribing data compared with their peers, paired with evidence-based messaging, and a concise statement summarizing the desired change in prescribing behavior. The Portrait program implements a series of pragmatic trials to improve prescribing where clinicians are randomized into an early intervention and a delayed control group.

The current study evaluates the impact of an antibiotic prescribing portrait and evidence summary focused on reducing overall antibiotic use and avoiding routine prescribing for common respiratory tract infections (upper respiratory tract infections, acute bronchitis, acute sinusitis) in primary care. The prescribing portrait title is "What are your antibiotic prescribing rates?" and is accompanied by a therapeutics letter (evidence summary) entitled "Avoid antibiotics for self-limited viral infections" and an introduction letter.

The portrait contains two key recommendations based on recent systematic reviews on the effect of antibiotic prescribing on antimicrobial resistance in primary care: 1) Reduce the number of your patient visits that end with an antibiotic prescription, and 2) Avoid routinely prescribing antibiotics for upper respiratory tract infections, acute bronchitis, and acute sinusitis. The first recommendation is accompanied by a bar graph showing the prescriber their number of antibiotic prescriptions per 100 patients in 2024 in comparison with the median practice in BC and an achievable target. The second recommendation is accompanied by a bar graph showing the prescriber's percentage of antibiotic prescriptions identified as likely unnecessary in 2024 in comparison with the median practice in BC and an achievable target.

The prescribing portrait data were generated using linked administrative health claims data from the BC Ministry of Health. Data access is provided according to the Information Sharing Agreement with the BC Ministry of Health (ISA 16-036). To maintain data security, data will be accessed via the Ministry of Health's Secure Analysis Environment, and include:

• BC Medical Services Plan (MSP) physician services data
• Hospital separations from the Discharge Abstracts Database (DAD)
• BC PharmaNet data (prescription drugs dispensed at community pharmacies)
• Client Roster (client demographic data)
• Practitioner Roster (practitioner demographic data)

7,626 physicians and nurse practitioners in British Columbia were randomized in an 80:20 ratio, with 80% assigned to receive the intervention materials early and 20% assigned to a delayed control group (6,100 intervention; 1,526 control). Clinicians in the early group will be mailed the intervention at study initiation (February 2026), while those in the delayed group will be mailed the same materials after an approximate 9-month delay. Study group assignment will be conducted using a random number generator by an independent analyst. Researchers selected this unequal allocation to facilitate earlier dissemination of the intervention to a larger proportion of clinicians while maintaining a control group for estimation of the intervention effect.

Researchers will use a modified intention-to-treat approach for all analyses, with clinicians analyzed based on their randomized assignment to early or delayed receipt of the prescribing portrait. Clinicians who opt out will be excluded from analysis. Intervention effects will be estimated using Poisson regression to estimate rates, rate differences and rate ratios for the outcome, with the delayed group serving as a contemporaneous control group to account for secular changes in prescribing.

The primary outcome is the weekly rate of new (incident) antibiotic prescriptions per practitioner. A prescription is considered "new" if the patient has not received an antibiotic from the same prescriber in the previous 30 days. Repeat prescriptions within an ongoing course of care are excluded.

Secondary outcomes are: 1) the weekly rate of likely unnecessary incident antibiotic prescriptions per practitioner, and 2) the weekly rate of likely unnecessary, condition-specific incident antibiotic prescriptions per practitioner for upper respiratory tract infections (URTI), acute bronchitis, and acute sinusitis.

Researchers will summarize baseline clinician characteristics by study group using descriptive statistics. To evaluate the durability of the intervention effect, researchers will assess primary and secondary outcomes at 1, 3, and 6 months, as well as over the full delay period (approximately 9 months).

Practitioner Inclusion Criteria:

Registered in 2024 with the BC Medical Services Plan (MSP) with:

• A valid MSP billing number;
• Status of Salaried, Private Practice, Temporary Licence, or Post Graduate;
• Prescribed >100 dispensed medications in 2024.

Exclusion criteria

• Previously opted out of the Therapeutics Initiative Portrait program

Patient Exclusion Criteria:

• Age <18 years at time of oral antibiotic dispensation;
• Received PharmaCare benefits through the Palliative Care program at any time during the baseline or study period;
• Hospitalized within 1 week prior to an antibiotic prescription at any time during the baseline or study period;
• On chronic suppressive antibiotic therapy (≥90 days' supply of any antibiotic dispensed) during the baseline or study period